Pfizer bid to expand Talzenna label in prostate cancer rejected by FDA

17 hours ago 1

Pfizer (NYSE:PFE) has suffered a setback in its bid to market its antitumor agent Talzenna for a wider group of U.S. patients with prostate cancer after the FDA declined to approve a label expansion for the PARP inhibitor.
Talzenna, already approved

Recommended For You